Vascular Dementia Market Size in the 7MM is expected to increase at approximate CAGR of 4.05% for the study period (2019-2032) from USD 2,230 million in 2021 to significant market size by 2032 | Companies- Charsire Biotechnology Corp, ProNeurogen Therapeu

The Vascular Dementia market report provides current treatment practices, Vascular Dementia emerging drugs, Vascular Dementia market share of the individual therapies, current and forecasted Vascular Dementia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Vascular Dementia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Vascular Dementia market.

Discover more about therapies set to grab major Vascular Dementia Market Share @ Vascular Dementia Market Size- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Vascular Dementia Market Report
• As per the assessment of DelveInsight, total prevalent cases of dementia in the 7MM were found to be 21,591,565 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 2.42% during study period.
• The diagnosed prevalent cases of dementia in the 7MM were found to be 11,344,408 in 2021, which are expected to increase at a CAGR of 3.60% for the study period of 2019-2032.
• The leading Vascular Dementia Companies include Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix Corp., and others
• Promising Vascular Dementia Pipeline Therapies include donepezil hydrochloride (Aricept), Cerebrolysin, 0.9% Saline Solution, Prospecta, Rivastigmine, Butylphthalide soft capsule, Akatinol Memantine 20 mg, Cilostazol, Aspirin, galantamine hydrobromide, and others
• PNA1, as a proof of concept study, is in FDA-approved Phase IIa pilot clinical trials for vascular dementia cardiac disease patients. Patients are currently enrolling in the trials.
• ProNeurogen is a neuroinflammation company developing a platformof the novel, proprietary drug candidates to treat: cognitive impairment due to vascular dementia, mixed dementia, traumatic brain injury, and chronic and neuropathic pain.
• BAC (also called CSTC1, CHARSIRE Trauma Complex 1), a component of soybean extraction developed by Charsire Biotechnology Corp, is under investigation to treat a variety of diseases, including AD and VaD. BAC is a vapor fraction from seeds of Glycine max (L.) Merr. BAC in its studies showed to promote the proliferation of neuroblastoma IMR-32 cells, and this observation may correlate to the improvement of the cognitive performance in the heavy metal-induced AD mice and the VaD-resembled rats when treated with BAC.
• Recent pivotal clinical trials of drug candidates that target amyloidbeta and Tau protein have failed due to not knowing the exact mechanisms that give rise to the pathology of Alzheimer's disease. The pharmacological studies of BAC indicated that BAC might improve Alzheimer's disease and Vascular Dementia conditions through anti-inflammatory routes. This will be further confirmed in Phase III pivotal studies.

To explore more information on the latest breakthroughs in the Vascular Dementia treatment landscape of the report, click here @ Vascular Dementia Market Outlook- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vascular Dementia Overview
Vascular dementia (VaD) is an etiological category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypoperfusion affecting brain regions important for memory, cognition, and behavior. Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and the number of vascular changes.

Vascular Dementia Epidemiology Segmentation in the 7MM
• Vascular Dementia Prevalent Cases
• Vascular Dementia Diagnosed Prevalent Cases
• Vascular Dementia Age-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Vascular Dementia Epidemiology Trends @ Vascular Dementia Epidemiological Insights- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Vascular Dementia Emerging Drugs

BAC: Charsire Biotechnology Corp
BAC (also called CSTC1, CHARSIRE Trauma Complex 1), a component of soybean extraction developed by Charsire Biotechnology Corp, is under investigation to treat a variety of diseases, including AD and Vascular Dementia. BAC is a vapor fraction from seeds of Glycine max (L.) Merr. BAC in its studies showed to promote the proliferation of neuroblastoma IMR-32 cells, and this observation may correlate to the improvement of the cognitive performance in the heavy metal-induced AD mice and the Vascular Dementia-resembled rats when treated with BAC.

PNA1: ProNeurogen Therapeutics
PNA1, a rationally-designed Angiotensin-(1-7) Mas receptor agonists that have enhanced BBB penetration half-life and designed to inhibit chronic inflammatory pathways in both the brain and the cerebrovasculature endothelium. These pathways are involved in vascular dementia and neuropathic pain. These novel peptide formulations are designed to act on Mas receptors (MasR) within the brain vascular endothelium and neuronal cells and microglia to decrease brain ROS production and neuroinflammation. The drug candidate is based on technology developed at the University of Arizona.

Vascular Dementia Market Outlook
Vascular dementia is a common condition with no effective approved pharmacological treatments available. Vascular dementia arises from ischemic insults such as hemorrhage and hypoperfusion that trigger neurodegeneration by depriving nerve cells of oxygen and glucose. Vascular Dementia has multifactorial etiopathology, diverse clinical manifestations, and multiple clinical subtypes. Moreover, the diagnostic criteria are not consistent worldwide. Although patients with Vascular Dementia constitute the second-largest dementia population, treatment data are lacking. There are no effective pharmacological compounds approved for the treatment of vascular dementia in any jurisdiction worldwide. Controlling medical conditions that impact cardiovascular health is recommended to prevent further decline. For example, medications can be prescribed to control blood pressure, cholesterol, heart disease, and diabetes. Aspirin or other drugs may be prescribed to prevent clots from forming in blood vessels

To know more about Vascular Dementia Therapies options, visit @ Vascular Dementia Therapeutics Market- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Vascular Dementia Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Vascular Dementia Companies- Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix Corp., and others
• Vascular Dementia Pipeline Therapies- donepezil hydrochloride (Aricept), Cerebrolysin, 0.9% Saline Solution, Prospecta, Rivastigmine, Butylphthalide soft capsule, Akatinol Memantine 20 mg, Cilostazol, Aspirin, galantamine hydrobromide, and others
• Vascular Dementia Market Dynamics: Vascular Dementia Market Drivers and Barriers

Discover more about Vascular Dementia Drugs in development @ Vascular Dementia Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Vascular Dementia Market Overview at a Glance
4. Vascular Dementia Market: Future Perspective
5. Executive Summary of Vascular Dementia
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drugs
11. Vascular Dementia: Seven Major Market Analysis
12. KOL Views
13. Market Drivers
14. Market Barriers
15. SWOT Analysis
16. Unmet Needs
17. Reimbursement and Market Access
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Learn more about the Vascular Dementia Pipeline Therapies in clinical trials @ Vascular Dementia SWOT Analysis, Unmet Needs, Reimbursement, and Patient Journey- https://www.delveinsight.com/sample-request/vascular-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.